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ARTICLE
Positron emission tomography imaging of novel
AAV capsids maps rapid brain accumulation
Jai Woong Seo 1,2, Elizabeth S. Ingham2, Lisa Mahakian2, Spencer Tumbale1, Bo Wu1, Sadaf Aghevlian1,
Shahin Shams 2, Mo Baikoghli3, Poorva Jain1, Xiaozhe Ding 4, Nick Goeden4, Tatyana Dobreva4,
Nicholas C. Flytzanis 4, Michael Chavez5, Kratika Singhal6, Ryan Leib 6, Michelle L. James1,
David J. Segal 7, R. Holland Cheng 3, Eduardo A. Silva 2, Viviana Gradinaru 4 &
Katherine W. Ferrara 1✉
Adeno-associated viruses (AAVs) are typically single-stranded deoxyribonucleic acid
(ssDNA) encapsulated within 25-nm protein capsids. Recently, tissue-specific AAV capsids
(e.g. PHP.eB) have been shown to enhance brain delivery in rodents via the LY6A receptor on
brain endothelial cells. Here, we create a non-invasive positron emission tomography (PET)
methodology to track viruses. To provide the sensitivity required to track AAVs injected at
picomolar levels, a unique multichelator construct labeled with a positron emitter (Cu-64,
t1/2= 12.7 h) is coupled to the viral capsid. We find that brain accumulation of the PHP.eB
capsid 1) exceeds that reported in any previous PET study of brain uptake of targeted
therapies and 2) is correlated with optical reporter gene transduction of the brain. The PHP.
eB capsid brain endothelial receptor affinity is nearly 20-fold greater than that of AAV9. The
results suggest that novel PET imaging techniques can be applied to inform and optimize
capsid design.
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Therapeutic delivery to the brain has traditionally beenlimited in volume. The background level of protein/nanotherapeutics reaching the brain is on the order of 0.1
percent injected dose per cubic centimeter (% ID/cc)1, necessi-
tating more efficient methods of delivery. Engineered adeno-
associated viruses (AAVs), single-stranded deoxyribonucleic acid
(ssDNA) encapsulated within 25-nm protein capsids, have
recently shown potential to greatly increase transduction as
compared with previous therapeutics2–4. AAVs can infect divid-
ing and non-dividing cells and result in highly efficient long-term
transduction in a broad range of tissues5,6. This is particularly
significant as AAV gene therapy has a solid safety profile, was first
approved by the FDA in December 20177 and more than 200
clinical trials have been conducted since 19898. Recently, AAVs
have been shown capable of delivering CRISPR-Cas9 gene
silencing in vivo9, expanding their potential utility. Using a
directed evolution approach to viral capsid engineering and
selection, AAV-PHP.eB, containing a 2-mer substitution and 7-
mer peptide insertion in a surface exposed loop of the capsid,
enhanced neuronal transduction throughout the brain compared
to the conventionally used AAV serotype 9 (AAV9)3. This 40 to
90-fold increased efficiency is believed to result from a novel
interaction between virus and the brain endothelial cell receptor
LY6A10,11.
In vivo imaging has great potential to contribute to the design
and optimization of AAVs. The biodistribution of viral vectors
has previously been evaluated by real-time PCR, Southern blot-
ting of the transduced gene, western blotting, immunohis-
tochemistry (IHC), and in vivo imaging of reporter proteins12.
Many of these methods are invasive, relying on small quantities of
tissue at a single site and/or time point13. In vivo imaging can
determine the reporter protein level expressed from a transduced
gene across an entire region of interest (ROI) over time; however,
the underlying mechanisms for differences in the reporter protein
cannot be directly identified with this approach. Development of
a labeling method for non-invasive pharmacokinetics (PK) stu-
dies is valuable for several reasons. First, in vivo imaging can
directly and non-invasively assess endothelial receptor binding at
multiple time points. Second, PK can be non-invasively assessed
even with repeated administration, the potential for which
increases since capsid engineering and cargo development also
address issues related to AAV neutralization and
immunogenicity5,14,15. Third, quantitative imaging techniques
facilitate comparisons across strains and species.
We therefore set out to develop an imaging method to track
therapeutic viral constructs and quantify their binding to endo-
thelial surface receptors. Positron emission tomography (PET)
provides an ideal non-invasive method to track viral constructs in
brain-related and other diseases16. In particular graphical analysis
of plasma and tissue radiotracer uptake at multiple time points
produces a linear plot, the slope of which is related to the number
of available tracer binding sites. PET facilitates the interpretation
of endothelial binding and the quantification of reversible
receptor binding17,18. This provides a unique noninvasive
assessment of AAV uptake.
PET imaging has not previously been applied for systemic
AAV tracking. Surface modification of AAVs has previously
focused on tagging fluorophores19–24 to PEG25,26, or adding
peptides27,28, antibodies23, or small molecules29 to the capsid.
Given that most earlier generations of AAV and other viral
therapies were not designed for specific organ targeting, imaging
studies labeled multiple lysines on the capsid with a lesser impact
on organ-specific endothelial targeting and transduction30.
Recently, the AAV capsid was labeled with I-124, but the study
was limited to direct intracranial injection to the brain and
therefore did not focus on the receptor binding characteristics or
endothelial accumulation31. Alternatively, reporter gene imaging
has been used to measure transduction but cannot quantify PK32.
Thus, our study fills a void in PET imaging of the PK of novel
capsids.
The challenge in monitoring the PK of systemically injected
AAVs with PET (particularly with high time resolution) is to
achieve a trackable level of radioactivity while matching the half-
life of the positron emitter to AAV circulation half-life, which
ranges from minutes to days33. An additional challenge is to
minimize conjugation to key AAV surface features. High molar
activity (MA) positron emitters, such as F-18 and Ga-68, typically
have a short half-life (t1/2 of 110 and 68 min, respectively); thus,
limiting their utility (Fig. 1a). The dose for systemic adminis-
tration of AAVs in mice is low; ~1011–12 vector genomes (vg) are
injected, corresponding to 0.2–2 pmol of AAVs. Cu-64 has a half-
life of 12.7 h and is therefore well suited to the AAV half-life in
blood34; however, combining 64CuCl2 (MA, ~20 μCi/pmol) and 2
pmol of AAVs yields ~40 μCi of labeled AAVs when the labeling
ratio of Cu-64 to AAVs is 1:1. Real-time high resolution imaging
is impaired with this very low level of radioactivity. In order to
facilitate high signal-to-noise (SNR) PET imaging at a low AAV
dose, we have therefore synthesized a bifunctional multichelator
that increases the MA of 64Cu/molecule up to 10 times compared
to a single chelator.
Our study highlights the potential to use PET imaging to track
viral capsids after systemic injection, facilitating noninvasive
quantitation of organ accumulation and clearance and endothelial
receptor binding. The multichelator approach developed here is
applied for optical microscopy, system-level PET imaging and
autoradiography. Based on these analyses, we find that brain
accumulation of PHP.eB, a novel AAV9 derivative with high
brain tropism, exceeds that reported in previous PET studies of
brain uptake of targeted therapies. Further, the high signal-to-
noise ratio obtained with the multichelator approach can be
exploited to quantify endothelial receptor affinity over the first 30
min after injection. Here, brain affinity of the PHP.eB capsid is
enhanced nearly 20-fold as compared with the well-established
AAV9 capsid. Most importantly, the labeling method retains the
transduction efficacy of the AAV and can be applied in future
studies to inform and optimize the design of AAVs and other
viral capsids.
Results
Syntheses of multichelators. We have developed a bio-
orthogonal approach for coupling a multichelator and AAV,
based on conjugation to AAV surface lysines and cysteines and
used this approach to compare the PK of AAV9-PHP.eB (AAV9-
PHP.eB is denoted as PHP.eB hereafter) with AAV9 and AAV9-
tetracysteine (AAV9-TC). Conjugation to surface lysines was
previously shown to be feasible in fluorescence imaging where
AAV surface lysines were modified with a fluorescent dye, which
facilitated AAV tracking without hampering transduction effi-
ciency19–22,35. Based on surface solvent accessibility in the X-ray
structure of the AAV9 capsid30, the estimated number of exposed
lysines on AAV9 and PHP.eB ranges from 420 to 480 out of 1185
and 1245 total lysines, respectively (Fig. 1b). This includes 7–8
lysines per viral protein (VP), with one viral particle composed of
60 units of VP. We based the surface lysine labeling strategies on
inverse electron demand Diels–Alder reactions (IEDDA), which
offer a fast, quantitative (>50,000M−1S−1) orthogonal reaction36.
We modified a small number of the surface lysines with Tz-NHS
ester, followed by conjugation of the 64Cu-multichelator-
transcyclooctene (TCO), (NOTA)8-TCO (Fig. 1c). Multi-
chelator-maleimide, (NOTA)8-MI, was employed (Fig. 1d) to
label AAV9-TC. Notation describing the labeled AAVs (e.g.
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64Cu-PHP.eB) is defined in Fig. 1c, d. In order to confirm that the
lysine attachment does not alter receptor binding, we compared
labeling with this approach to labeling of cysteines available on a
tetracysteine (TC) engineered version of AAV9 using a
maleimide-thiol reaction of the multichelator (Supplementary
Fig. 1). In this virus, an (HRWCCPGCCKTF) motif was inserted
at amino acid 139 (residue numbered by VP1 sequence) of the
AAV9 capsid proteins (AAV9-139). The insertion site is located
in the N-terminal disordered region of capsid proteins VP1 and
VP2. A similar modification was made in AAV9 and was shown
to be accessible by labeling reagents without compromising viral
integrity24.
The multichelators, (NOTA)8-TCO and (NOTA)8-MI, were
synthesized through a solid phase reaction. Multistep coupling of
Fmoc-Lys(Fmoc)-OH from polyethylene glycol(PEG)27-Lys(Boc)
on resin afforded eight branched amines, further coupled with
tert-Bu-NOTA-OH. A PEG spacer was included to separate the
multichelator and reactive functional group. After cleavage of
(NOTA)8-NH2 (Supplementary Fig. 2a, 1) from the resin, 1 was
further functionalized to (NOTA)8-TCO (Supplementary Fig. 2a,
2) and (NOTA)8-MI (Supplementary Fig. 2a, 3). In all, 2 and 3
were isolated by HPLC presented monoisotopic mass peaks at
5026.67 (calculated mass: 5026.85 Da) and 4937.66 (calculated
mass: 4937.74 Da) in MALDI mass analysis (Supplementary
Fig. 2a), respectively. For optical studies of PHP.eB and AAV9
conjugated with the multichelator, (NOTA)8-A555-TCO with a
cysteine introduced to conjugate A555-maleimide was synthe-
sized as shown in Supplementary Fig. 2b. The mass (M+H+) of
a b
c
d
Fig. 1 Strategy for labeling AAVs with a positron emitter. a Table presents the number of AAVs systemically injected and the molar activity of positron
emitters. b Solvent accessible surface of AAV9 capsid30 (PDB ID:3UX1) displayed by PyMOL software. Insets highlight a trimer around a threefold axis.
Orange and green color represent lysine and cysteine residues, respectively. Solvent radius is set as 1.4 angstrom. AAV capsid is composed of
60 structurally identical viral protein subunits (VPs) with 1:1:10 ratio of VP1:VP2:VP3. c, d are the labeling schemes of AAV-PHP.eB, AAV9, and AAV9-TC.
c Surface modification with multichelators (MC) on lysine residues in capsids. (NOTA)8-TCO (incorporating a PEG27 spacer) is employed for the
radiolabeling of Tz-AAV9 or Tz-PHP.eB after reaction of Tz-NHS ester with AAV9 or PHP.eB. (i, tetrazine-PEG5-NHS (Tz-NHS) ester, 1x PBS (pH 8), 4 °C,
overnight dialysis in 20 kDa molecular weight cut-off (MWCO) membrane). d The site-specific radiolabeling on cysteine residues in AAV9-TC was
employed with the multichelator-maleimide conjugate ((NOTA)8-MI) incorporating Cu-64 after the reduction of tetracysteine with TCEP (ii, TCEP in 1x
PBS (pH 7.0–7.5)). Asterisk indicates average molar radioactivity of Cu-64 from commercial vendor as used in this study.
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(NOTA)8-cys(SH)-NH2 (4), (NOTA)8-A555-NH2 (5) and
(NOTA)8-A555-TCO (6) verified with MALDI mass analysis
were detected at 4874.54 (calculated mass: 4875.70 Da), 5844.85
(calculated mass: 5843.94) and 6245.47 (calculated mass:
6243.16), respectively.
Efficiency of Cu-64 incorporation on single and multichelator.
To assess the incorporation of copper on the multichelator,
increasing amounts of (NOTA)8-TCO were reacted with a known
amount of nonradioactive Cu-63 spiked with the radioactive Cu-
64, and the incorporation ratio was then compared with that
achieved with the single chelator (NOTA-TCO). We confirmed
that more than two single chelators, NOTA-TCOs, are required
to incorporate one copper molecule (Supplementary Fig. 3a), and
one multichelator, (NOTA)8-TCO, incorporated 5–8 copper
molecules (Supplementary Fig. 3b). Thus, the multichelator
achieves ~10 times higher molar radioactivity than the single
chelator (Supplementary Fig. 3).
Capsid surface modification maintains transduction efficiency.
To determine the maximum molar ratio of Tz-NHS and
(NOTA)8-TCO that can be incubated with PHP.eB:CAG-GFP
(and similarly (NOTA)8-MI with AAV9-TC:CAG-mNeonGreen)
without hampering its integrity, we monitored the AAV trans-
duction efficiency in HEK293T cells before and after labeling
(Fig. 2a, b, Supplementary Figs. 4 and 5). In previous studies, the
conjugation of NHS (succinimidyl ester) to AAVs typically pro-
ceeded under strong basic conditions (0.1 M Na2CO3, pH 9.3);
however, the reported procedures have been inconsistently
detailed, and the experimental conditions vary widely (summar-
ized in Supplementary Table 1). To avoid harsh conditions, the
reaction was performed at pH 8 by mixing PBS and Na2CO3 (v:v,
8:2), as is routinely exploited in preparation of antibody con-
jugates. Under this reaction condition, PHP.eB (4.2 × 1011 vg, 0.7
pmol particles) was incubated with Tz-NHS and followed an
IEDDA reaction with (NOTA)8-TCO (Supplementary Fig. 4a).
SDS-PAGE analysis of PHP.eBs labeled with (NOTA)8-TCO
clearly showed three VP bands with similar molecular weight to
the unmodified control PHP.eB (Supplementary Fig. 4b). Incu-
bation with a molar ratio of 500 and above resulted in additional
high molecular-weight protein bands (Supplementary Fig. 4b)
and a significant reduction in fluorescent-protein expressing cells
(Supplementary Fig. 4c). Both assays suggest that keeping the
molar ratio of (NOTA)8-TCO/PHP.eB below 500-fold maintains
transduction efficiency of HEK293T cells and prevents the
aggregation of capsid proteins after labeling of PHP.eB. Limits on
the concentration of the chelator were more restrictive with
AAV9-TC. AAV9-TC:CAG-mNeonGreen (5.8 × 1012 vg, 9.6
pmol) after reduction to HS-AAV9-TC by TCEP was reacted
with (NOTA)8-MIs at 14, 70, and 140 pmol (Supplementary
Fig. 5a). Multiple bands of over-labeled VPs were found when the
incubated (NOTA)8-MI/AAV9-TC ratio was 70-fold or more
(Supplementary Fig. 5b). For AAV9-TC, multiple bands likely
result from the non-specific maleimide conjugation with primary
amines as previously reported37. In this previous report, a similar
protein band shift occurred in SDS-PAGE at dye:protein ratios
>40:1. Irrespective of the multiple band formation, AAV9-TC
transduction efficiency was preserved at all levels of modification
(Supplementary Fig. 5c).
Under the optimized conditions, AAV9 and PHP.eB were then
labeled with multichelators that have been conjugated with Cu-64
following the procedure detailed in the Methods section.
Transduction efficiencies of Tz-AAV9 and -PHP.eB (modified
from AAV9:CAG-mNeonGreen and PHP.eB:CAG-GFP with Tz-
NHS, respectively) and HS-AAV9-TC (a reduced form of AAV9-
TC:CAG-mNeonGreen) were then compared with those of intact
AAVs in HEK293T cells in vitro (1 × 106 vg/cell). As assessed by
fluorescent green protein expression in HEK293T cell images,
fluorescent-protein transduction was similar at 24 h after
incubation with intermediates before and after modification
(Fig. 2a). Flow cytometry at 48 h confirmed the comparable
transduction efficiency of modified and unmodified AAVs for Tz-
AAV9 and -PHP.eB and HS-AAV9-TC (Fig. 2b). Most
importantly, the transduction efficiency of 63Cu-labeled PHP.
eB:CAG-GFP and PHP.eB:CAG-GFP in C57BL/6 mice was
evaluated to determine whether the multichelator influenced
viral delivery and GFP production in the brain at 3 weeks after
tail vein administration (1.5 × 1010 vg). The GFP mean fluores-
cence intensity (MFI) within the brain was similar (Fig. 2c, d, n=
4, n.s.) following injection of the unmodified (PHP.eB) or the
labeled AAV (63Cu-PHP.eB) and undetectable after saline
injection. Taken together, the results demonstrate that our
optimized labeling condition preserved the AAV’s functional
properties.
Characterization of radiolabeled capsid on viral proteins. The
viral protein (VP) bands were visualized via protein staining
(blue, 1st and 2nd lane), and the radiolabeled VP bands were
imaged with sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and autoradiography (gray, 3rd lane)
(Fig. 2e). The band location of the three VPs (blue bands)
between Tz-PHP.eB and 64Cu-PHP.eB, Tz-AAV9 and 64Cu-
AAV9 and HS-AAV9-TC and 64Cu-AAV9-TC were similar. The
relative radiolabeling of VP3 was greater than VP1 or VP2 for
PHP.eB and AAV9 (Fig. 2e), directly related to the ratio of
protein abundance for the three VPs, 1:1:10 (VP1, VP2, VP3).
AAV9-TC was generated by site-specific insertion of the
HRWCCPGCCKTF peptide motif at the VP1/VP2 interface at
the 139th amino acid24. As a result, the gel image from auto-
radiography of 64Cu-AAV9-TC showed the VP2 band as the
major radiolabeled VP whereas the protein staining (blue) of
64Cu-AAV9-TC was similar to the ratio of each VP (VP1:VP2:
VP3, 1:1:10) (right column image of Fig. 2e).
PHP.eB size was unchanged after 63Cu-multichelator labeling.
The size of 63Cu-labeled and unlabeled PHP.eB was 27.9 ± 0.64
and 27.1 ± 0.68 nm (n= 3), respectively, and detected as a single
peak (Supplementary Fig. 6).
Proteomic analysis of modified lysines on the capsid protein.
We first determined the lysine sites modified with Tz-NHS by
proteomic analysis. Mass lists from the analyses of excised gel
bands of VP1, VP2, and VP3 after reaction of PHP.eB with Tz-
NHS showed that tetrazines were predominantly incorporated on
two lysines (K557 and K567) (Supplementary Table 2), which
exist in all VPs. Importantly, the lysine at the 595th amino acid
located within the engineered peptide sequences (DGTLAVPFK),
critical for the distribution of PHP.eB to the brain and trans-
duction of its transgene3, remained unreacted. Based on the
crystal structure of AAV930, neither of the modified sites are
located in the core of the threefold-proximal spikes, the region
considered to be responsible for most virus-host interactions.
K567 is located in the valley between the spikes, while K557 is on
the distal shoulder (Fig. 2f). To the best of our knowledge, the two
sites have not been reported to be involved in receptor binding for
AAV9 derivatives.
Determination of the number of AAV labels. We compared
results from optical labeling and electron microscopy to deter-
mine the number of labels. We examined the number of labels per
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Fig. 2 Transduction and labeling efficiency of surface modified AAVs. a Fluorescence microscopy images of human embryonic kidney(HEK) 293T cells
after 24 h incubation with intact AAVs (upper row, PHP.eB, AAV9, and AAV9-TC) and corresponding modified AAVs (lower row, Tz-PHP.eB, Tz-AAV9,
and HS-AAV9-TC) at 1 × 106 AAV/cell. b Percentage of green fluorescent positive (GF+) HEK293T cells 2 days after incubation with unmodified AAVs
(PHP.eB, AAV9, and AAV9-TC, white bar with black circles) and the corresponding modified AAVs (gray bar with black squares), assessed by flow
cytometry. The frequency of GF+ cells treated with unmodified and modified AAVs was similar and distinct from non-treated (NT, black triangles) cells
(n= 4 per group). c Representative GFP images of sagittal brain sections from a C57BL/6 mouse at 3 weeks after tail vein administration of 63Cu-PHP.eB,
PHP.eB (1.5 × 1010 vg) or saline (negative control) and d mean fluorescence intensity (MFI) of sagittal brain sections (63Cu-PHP.eB: gray bar with black
squares, PHP.eB: white bar with black circles, saline: black triangles, n= 4). e SDS-PAGE of modified AAVs (Tz-PHP.eB, Tz-AAV9, and HS-AAV9-TC; lane
1) and radiolabeled AAVs (64Cu-PHP.eB, 64Cu-AAV9, and 64Cu-AAV9-TC; lane 2 and 3). The three bands depict viral protein (VP) 1–3 (L: standard
protein ladder). Lane 1–3 illustrate blue-stained VPs (lanes 1 and 2) and radiolabeled VPs (lane 3), respectively. f Illustration of AAV9 capsid with modified
lysines. Left: full view of AAV9, middle and right: top and side views of trimer viral proteins, respectively. The K557 (yellow) and K567 (red) lysine residues
are highlighted. g Field view of direct-electron cryoEM images of PEG(40 kDa)-AAV9 (left image) and enhanced projection images of selected
PEG(40 kDa)-AAV9 capsids (six right images). White arrows mark the 40 kDa PEG molecules extended from the selected AAV capsids. Data are shown
as mean ± SD. Brown-Forsythe and Welch ANOVA with Dunnett’s T3 multiple comparison test compares means (b, d). Significance is presented as n.s.
(not significant), *P≤ 0.05, **P≤ 0.01, and ***P≤ 0.001. Whole gel and gel autoradiography images and P values are shown in the source data. Scale bars:
100 μm (a), 2 mm (c), 50 nm (g, left), 20 nm (g, right).
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capsid using the multi-armed fluorescent label (Supplementary
Figs. 2b and 7a) combined with quantification of the AAV con-
centration through a titer. We applied this approach for both the
amine- and thiol-directed coupling approaches. Labeling with
200–350 equivalents of Tz-NHS and reaction with 10–15
equivalents of (NOTA)8-A555-TCO gave 5.4 ± 2.3 (n= 6) and
3.5 ± 3.0 (n= 8) labels per PHP.eB and AAV9 capsid, respectively
(Supplementary Table 3). AAV9-TC reduced by 100 equivalents
of TCEP and subsequently reacted with 20 equivalents of A555-
C2 maleimide yielded 0.5 ± 0.3 (n= 4) ea/vg of A555-AAV9-TC
(Supplementary Table 3).
Furthermore, since the 5 kDa size of the (NOTA)8-A555
conjugate on AAV9 was not reliably visualized on cryogenic
electron microscopy (cryoEM), we conjugated a larger label (PEG
(40 kDa)-TCO) (Supplementary Fig. 7b) to the capsid. This label
was conjugated to AAV9 (denoted PEG(40 kDa)-AAV9) using
the same conditions used for the in vivo imaging and was used to
visualize the number of labels per virus (Supplementary Fig. 7a).
PEG(40 kDa)-AAV9 was obtained from a reaction with Tz-AAV9
and 4 equivalents of PEG(40 kDa)-TCO and showed one to three
labels per capsid on cryoEM images (Fig. 2g).
AAV radiolabeling was achieved with high radiochemical
purity. The 20–35 pmol of (NOTA)8-TCO and (NOTA)8-MI
were enough to incorporate >99% of 1–2 mCi Cu-64. In situ
incubation of Tz-AAV9 and -PHP.eB and HS-AAV9-TC with
these multichelators yielded 64Cu-AAV9, -AAV9-TC, and -PHP.
eB to 2.2% (1.78 MBq (48 μCi)), 6.6% (4.88 MBq (132 μCi) and
7.5 ± 6% (3.9 ± 1.7 MBq (106 ± 45 μCi)), respectively (decay cor-
rected). Radiochemical purity of radiolabeled AAVs on instant
radio-thin layer chromatography was above 98%.
PET imaging quantified brain accumulation and receptor
binding. The PK and biodistribution of the 64Cu-AAV9, -AAV9-
TC, and -PHP.eB capsids (as defined in Fig. 1) were assessed in
C57BL/6 mice (n= 3/group) with PET/CT as illustrated in
Fig. 3a. The projection images acquired of AAVs revealed two
remarkable distinctions: the high brain uptake of PHP.eB and the
extended blood circulation of AAV9 (Fig. 3b, Supplementary
Movies 1–3). Blood circulation of AAV9 (t1/2= 5.0 h) was longer
than that of AAV9-TC (t1/2= 2.4 h) and PHP.eB (t1/2= 3.1 h)
(Fig. 3c, Supplementary Tables 4 and 5). The faster clearance of
PHP.eB from blood, as compared to AAV9, is expected due to
rapid uptake within the brain (Supplementary Movie 2a at 4 h).
The mechanism for the enhanced clearance of AAV9-TC has not
been fully characterized; however, the tetracysteine motif
(HRWCCPGCCKTF) on AAV9-TC can remain reactive after
reduction by TCEP, and S-thiolation by serum proteins38 can
reduce stability, potentially resulting in a protein corona or
aggregation over time39. Thus, while the initial (30 min) receptor
binding is expected to be similar, clearance from blood through
the liver and intestine (over hours) is expected to be enhanced for
AAV9-TC (Supplementary Movie 3a at 4 h). Brain accumulation
of PHP.eB was greater at all time points than that of AAV9 (n=
3, P= 0.0096 at 0 h, P= 0.0004 at 4 h, P= 0.0007 at 21 h) and
AAV9-TC (n= 3, P= 0.0116 at 0 h, P= 0.0003 at 4 h, P= 0.0006
at 21 h) (Fig. 3c, Supplementary Table 6). Maximum uptake (%
ID/cc) of 64Cu-PHP.eB in the entire brain was 35% ID/cc, with
the spatial maximum observed in the midbrain (Fig. 3d) and
strong midbrain uptake clearly visualized in the projected PET/
CT brain image (Fig. 3e). In addition, in order to assess the PK of
multichelator-labeled PHP.eB compared to that of PHP.eB, we
performed classical qPCR. Un-labeled PHP.eB and (NOTA)8-
A555-PHP.eB cleared at a similar rate from the blood pool
over 21 h (t1/2= 4.8 h vs 5.3 h, respectively) (Fig. 3f, left,
Supplementary Tables 4 and 7) and the blood clearance was
similar to that observed by PET (Fig. 3c). The biodistribution of
PHP.eB and (NOTA)8-A555-PHP.eB was similar in the major
organs such as the brain, heart, liver, spleen, kidney and blood
(Fig. 3f, right, Supplementary Table 8).
Sliced sagittal brain images in the cerebral cortex, thalamus,
midbrain and cerebellum from PET/CT (after 21 h), autoradio-
graphy (after 21 h), and ex vivo GFP fluorescence (after 3 weeks)
showed a consistent distribution of the viral capsid tag and
corresponding transduced GFP protein expression (Fig. 3g,
Supplementary Fig. 8). PHP.eB accumulation in the brain was
then analyzed in dynamic 5-min intervals over the first 30 min.
4% and 10% ID/cc of PHP.eB was bound at 5 and 30 min,
respectively, whereas AAV9 and AAV9-TC accumulation was
<1% ID/cc (Fig. 3h, Supplementary Fig. 8). Furthermore, Logan
plots, based on a reversible accumulation model, demonstrated
that the 30 min accumulation in brain was greater for PHP.
eB»AAV9 ~ AAV9-TC, with a distribution volume of 0.210,
0.011, and 0.011, respectively (Fig. 3h). Thus, the affinity of PHP.
eB for the brain endothelium is estimated to be 20-fold higher
than for AAV9 and AAV9-TC. The receptor affinity of AAV9
was identical for the two labeling methods as assessed by the
initial 30-min Logan plot (Fig. 3h).
Multichelator does not alter PHP.eB endothelial accumulation.
We employed two optical probes: a probe in which an optical dye
(A555-NHS ester) was attached to the native capsid lysines and a
second optical probe ((NOTA)8-A555-TCO) conjugated to the
multichelator construct in a manner similar to the (NOTA)8-
TCO conjugate (Supplementary Fig. 7a). The binding of A555-
PHP.eB, A555-AAV9 (Supplementary Fig. 9), (NOTA)8-A555-
PHP.eB (Fig. 3i) or (NOTA)8-A555-AAV9 (Supplementary
Fig. 10) to the brain endothelium, observed by confocal micro-
scopy at 4, 24, and 48 h after injection (Z-stack images in Sup-
plementary Movie 4), showed that punctate clusters were
observed at 4 h after injection. The fluorescence intensity gra-
dually diminished by 24 h and was similar to saline injection
(Supplementary Fig. 10) at 48 h. Taken together, the optical and
PET images suggest that the early-bound PHP.eB crossed the BBB
within 48 h and specific and effective binding of PHP.eB to the
brain endothelium was confirmed.
PET imaging elucidates strain and treatment-dependent PK.
Since mouse strain dependence of PHP.eB BBB transcytosis has
been reported10,40, the PK, brain uptake and biodistribution of
64Cu-PHP.eB were assessed by comparing BALB/c and C57BL/6
mice (Fig. 4a, Supplementary Table 9). Dramatically-reduced
brain uptake of 64Cu-PHP.eB was confirmed in BALB/c with
respect to C57BL/6 mice from the time-activity curve over 21 h
(Fig. 4a) (n= 3, P= 0.0048 at 0 h, P= 0.0002 at 4 h, P= 0.004 at
21 h) and PET/CT images at 0 h (Fig. 4b). Similar results (% ID/g)
were observed in the brain radioactivity from the biodistribution
at 21 h (Fig. 4c, n= 3, P= 0.0193). In addition, the uptake of
PHP.eB was greater in the liver of BALB/c than C57BL/6 mice
(n= 3, P= 0.0627 at 4 h) (Fig. 4d, e and Supplementary
Table 10). While the enhanced liver accumulation is anticipated
given the lack of brain accumulation, a strain-specific immune
response has also been reported to enhance liver accumulation in
the BALB/c strain41,42. Further, the circulation time of PHP.eB
(3.1 h) in the BALB/c mouse (2.4 h) was slightly lower than that
in C57BL/6 mice (Fig. 4a, Supplementary Table 4). The results
reaffirm the reduced brain uptake in BALB/c mice, which, unlike
C57BL/6 mice, lack the LY6A receptor that the engineered PHP.
eB binds to10; however, other differences also exist in the PK
between strains.
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Previously, pretreatment with neuraminidase (NA) in vitro and
in vivo, was reported to expose terminal N-linked galactose and
enhance AAV9 binding43,44. In our study, nasal administration of
NA was followed by IV injection of 64Cu-PHP.eB and
biodistribution at 21 h in BALB/c mice. Lung and brain
accumulation were increased by NA administration 1.4 (n= 3,
P= 0.0229) and 2.0-fold (n= 3, P= 0.0364), respectively (Fig. 4f).
The treatment by NA also increased the PHP.eB circulation time
from 2.4 h to 5.6 h (Fig. 4a). However, the increased accumulation
was relatively small as compared to the differences in brain
accumulation of PHP.eB between strains.
Discussion
We found that radiolabeling AAVs with a unique multichelator
construct allows for a detailed and quantitative study of AAV
biodistribution and pharmacokinetics. Following conjugation of a
dendrimer-like radioactive tag to novel AAVs, the fraction of
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radioactivity delivered to the brain was extraordinarily high, thus
demonstrating the potential use of AAVs as carriers. PET, with
appropriate analytic methods, was applied to noninvasively
quantify the endothelial receptor binding with a resolution of
minutes. We found that Logan analysis is particularly important
for characterizing the binding of novel AAV capsids as a rapid
and largely irreversible accumulation occurs on the endothelium
of the target tissue. No alternative technique can quantify binding
of viral capsids in real time; such information is critically
important for capsid engineering and for the identification of the
endothelial receptors responsible for AAV accumulation and
transcytosis.
Recent reports indicate that enhanced brain transduction by
PHP.eB in C57BL/6 mice requires an LY6A receptor-mediated
pathway that is independent of galactose and is absent in BALB/c
mice and non-human primates10. 64Cu-PHP.eB can be exploited
as a non-invasive tool to measure endothelium binding mediated
by the LY6A receptor in various mouse strains and other species.
Furthermore, the binding of serotype AAVs to the AAV receptor
(AAVR), identified as a critical host factor for infection of
naturally-occurring AAVs45, can be assessed by a simple blocking
study with novel AAVs.
Optical imaging of the tagged capsid validated the accumula-
tion of the capsids on the brain endothelium within minutes and
Fig. 3 PET and optical imaging-based assessment of AAV pharmacokinetics in C57BL/6 mice. a Experimental setup for region of interest (ROI) analysis
(0, 4, and 21 h) and biodistribution (21 h) of 64Cu-PHP.eB, -AAV9, and -AAV9-TC. PET images are acquired at 0, 4 and 21 h after AAV tail vein
administration. b Projected PET/CT images at 4 (left) and 21 h (right) (H heart, L liver, S spleen, B brain). c Time activity curves (over 21 h) and dmaximum
brain uptake (at 4 h) of 64Cu-PHP.eB (magenta triangle), 64Cu-AAV9 (black circle), and 64Cu-AAV9-TC (turquoise square) from the ROI analysis of blood
and brain (n= 3) after tail vein administration. e Representative projected PET/CT image at 4 h of 64Cu-PHP.eB within the brain (B brain, JV jugular vein).
f PK (left) and 21-h biodistribution (right) of PHP.eB (n= 3, black circle) and (NOTA)8-A555-PHP.eB (n= 4, black squares) obtained by qPCR. g Sliced
PET/CT, autoradiography and GFP images of sagittal section of mouse brain (CB cerebellum, M midbrain, Th thalamus, CC cerebral cortex, S striatum)
acquired at 21 h, 21 h and 3 weeks, respectively, after tail vein injection of 64Cu-PHP.eB for PET/CT and autoradiography and non-radioactive 63Cu-PHP.eB
for the GFP image. h 64Cu-AAVs brain accumulation (n= 3 per group) measured 30min after tail vein administration (left) and Logan plots (right) of brain
uptake rate after AAV administration. i Representative confocal images of (NOTA)8-A555-PHP.eB (red) on brain endothelium (green) acquired 4, 24, and
48 h after tail vein injection. White arrows indicate (NOTA)8-A555-PHP.eBs (red). Data are shown as mean ± SD. One-way ANOVA with Tukey’s multiple
comparison test (c, d, and h (left)) compared means of the three groups. Multiple unpaired t-tests with the Holm-Sidak method with alpha= 0.05
compared the means in f. Significance: n.s. (not significant), *P≤ 0.05, **P≤ 0.01, and ***P≤ 0.001. P values are shown in the source data. Intensity values
in b, d, e, and (g, left) are percent injected dose per cubic centimeter (% ID/cc). Scale bars: 2 mm (g), 25 μm (i).
a
d e f
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Fig. 4 Strain and neuraminidase-dependent pharmacokinetics of 64Cu-PHP.eB. a Time activity curves of PHP.eB obtained from region of interest (ROI)
analysis of blood (left) and brain (right) from C57BL/6 (black circle), BALB/c (turquoise square), and neuraminidase-treated BALB/c (magenta triangle)
mice over 21 h (n= 3 per group). Radioactivity from ROI analysis is presented as % ID/cc. b Representative PET/CT projection images (B brain, H heart, L
liver) acquired over 30min after tail vein injection of 64Cu-PHP.eB to C57BL/6 and BALB/c mice. c Biodistribution (% ID/g) of 64Cu-PHP.eB in brain (left)
and blood (right) in C57BL/6 (gray bar with black squares) and BALB/c (white bar with black circle) mice at 21 h (n= 3). d Sliced PET/CT image (H heart,
L liver) at 4 h after tail vein injection of 64Cu-PHP.eB. e Time activity curve of 64Cu-PHP.eB measured from C57BL/6 (black circle) and BALB/c (turquoise
square) livers (n= 3). f Biodistribution (21 h) of 64Cu-PHP.eB in blood (left), brain (middle), and lung (right) from BALB/c with no treatment white bar with
black circle) versus BALB/c mice treated with neuraminidase (gray bar with black square) (n= 3). Data are shown as mean ± SD. For statistical analysis, a
one-way ANOVA with Tukey’s multiple comparison test in a was performed to compare means of three groups (C57BL/6 vs BALB/c: turquoise, C57BL/6
vs BALB/c (neuraminidase): magenta, BALB/c vs BALB/c (neuraminidase): black) at each time point. Unpaired two-tailed Welch’s t-test was performed in
c, (e, 0, 4, and 21 h) and f. Significance is presented as *P≤ 0.05, **P≤ 0.01. P values are shown in the source data. Maximum and minimum intensity
values of PET/CT images in b, d are presented as percent injected dose per cubic centimeter (% ID/cc).
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the elimination of the punctate fluorescence on the endothelium
over 24 h. Given the very small size of the AAVs (25 nm),
tracking of their fluorescence within the brain was not feasible.
PET imaging complemented the information in the optical image
by demonstrating that the accumulated radioactivity remains
within the brain over 21 h. Classical pharmacokinetic analysis
based on a PCR further validated the brain accumulation. Given
that the radioactivity was tagged to the capsid surface, the dis-
tribution of radioactivity throughout the brain suggests that the
capsids were transcytosed across the BBB. This observation
supports previous reports of AAV transcytosis across the BBB, as
observed in vitro46. Combined PET and optical reporter gene
imaging demonstrated that the pattern of transduction within the
brain was similar to the distribution of the radioactive tag.
The stoichiometry of fluorophore-TCO conjugates on the
surface of AAV9 and PHP.eB was on average four labels per
particle. Labeling of a fluorescence-maleimide conjugate on
AAV9-TC conferred 0.6 label per capsid. CryoEM of AAV9
conjugated with PEG(40 kDa) similarly showed 2–3 copies of
extended PEG-string density per capsid. Our AAV surface
modification with tetrazine-NHS ester retained transduction
efficiency in HEK cells and in in vivo transduction studies. Fol-
lowing conjugation with the 5 kDa multichelator at a multi-
chelator:AAV ratio of 1:2 PHP.eB, binding to the brain
endothelium and transduction were maintained. Future work will
focus on optimizing the number and size of the conjugated tags.
Here, we minimized the number of tags per AAV in the in vivo
studies of transduction to minimize any effect on transport. Given
the relatively small loading capacity of AAVs, the potential to
conjugate additional cargo to the capsid could be transformative.
Multiple gene editing components, complementary therapeutics
or additional imaging tags can be attached to the surface.
The predominantly-labeled lysines of each viral protein within
PHP.eB were K557 and K567. K61, K92, K528, K618, K696, and
K700 were modified in a smaller fraction of capsids (Supple-
mentary Table 2). We speculate that K557 and K567 are sus-
ceptible to reaction with the NHS-ester and that this is the basis
of their enhanced modifications. The variable region VII (aa545-
aa558), including K557, is located within a region of the AAV
capsid associated with liver transduction47 and delayed blood
clearance30,33; however, to our best knowledge, there is no report
on the direct involvement of K557 or K567 in host receptor
binding. Recently, unnatural amino acids (UAA) bearing an azide
were site-specifically engineered in AAV2 (at aa 587) and AAV-
DJ (a derivative of AAV8, at aa 589) capsids and utilized to
conjugate oligonucleotides48. Specific protocols can also be
developed for labeling of other capsids. For example, there is a
lysine adjacent to K557 on AAV2 and adjacent to K567 on AAV1,
6, 8, 9, and 10 (Supplementary Table 2). Therefore, addition or
substitution of lysines, cysteines or UAAs within these sequences
or other AAVs can also provide a unique labeling site.
Finally, the PET method developed here to monitor binding
and pharmacokinetics will be paired with PET reporter gene
imaging in future work. A PET reporter gene based on pyruvate
kinase (PKM2) has been shown to have low background in the
brain and can be packaged within AAVs49. PKM2 can be used
with the reporter probe [18F]DASA-2349, which is permeable to
the blood-brain barrier in order to monitor brain transduction
over months or years. In the future, we will couple this tracer with
the PET tag described here.
Methods
Materials and reagents. All solvents were purchased from Fisher Chemical,
Sigma-Aldrich and Acros. The reagents and materials for multichelator synthesis
were purchased from Novabiochem, Click Chemistry Tools and Biotage. PEG27
spacers were purchased from Chem-Impex International Inc. and Polypure. PEG
(40 kDa)-amine (Creative PEGWorks) was purchased from Fisher Scientific. For
the capsid SDS-PAGE, the gels, buffer, standard ladder and protein staining
reagents were purchased from ThermoFisher Scientific. AFDye555-maleimide
(Fluoroprobes), AlexaFluor555-NHS ester (ThermoFisher Scientific) and
AlexaFluor555-C2-maleimide (ThermoFisher Scientific), each with 555 excitation
max and 580 emission max, are denoted as A555 throughout. The detailed list of
materials and reagents is in the Supplementary Methods.
Cell line and AAVs. Human embryonic kidney cells (HEK293T) were obtained
from ATCC (CRL-1573). AAV9, AAV9-TC, and PHP.eB packaging including
CAG-mNeonGreen or CAG-DIO-GFP were prepared as described in the Supple-
mentary Methods section entitled “Preparation of AAV9, AAV9-TC, and PHP.eB”.
All AAVs were used within two months of preparation. AAV-PHP.eB packaging
CAG-GFP was purchased from Addgene (#37825-PHP.eB). All AAVs used for
in vitro/in vivo transduction, PET/CT, and optical studies are summarized in
Supplementary Table 11.
Synthesis of (NOTA)8-NH2. Branched (NH2)8-NH2 was synthesized on rink
amide resins (0.49 mmol/g, 0.15 g) in a microwave-assisted solid phase synthesizer
(Initiator+Alstra, Biotage) as shown in Supplementary Fig. 2a. Sequential cou-
pling reaction was programed to be performed at 75 oC for 5 min with Fmoc-lys
(Boc)-OH (3 equivalents, 1.47 mmol, 113 mg), 0.2 M Fmoc-PEG27-OH (3
equivalents, 1.47 mmol, 372 mg), 0.2 M Fmoc-lys(Fmoc)-OH (3 equiv., 1.47 mmol,
131 mg), 0.2 M Fmoc-lys(Fmoc)-OH (5 equivalents, 2.45 mmol, 219 mg), and 0.2
M Fmoc-lys(Fmoc)-OH (4.9 equivalents, 439 mg) with 0.1 or 0.5 M HBTU (one
equivalent of each amino acids) and 0.2 M DIPEA (two equivalents of each amino
acids). The volume of each coupling reaction was maintained to be 3–5 mL DMF.
After drying resins under a vacuum, NOTA-bis(t-bu ester) (10 equivalents of
primary amine on resin, 100 mg, 0.24 mmol) was manually further coupled to the
lysine residue (eight amines per mole loading level, 0.25 mmol/g, 100 mg, 0.025
mmol) on resin with HBTU (89 mg, 0.24 mmol) and DIPEA (83 mg, 0.64 mmol) in
DMF (2 mL). NOTA-bis(t-bu ester) conjugation was monitored by TNBS assay.
When the TNBS test was positive, NOTA-bis(t-bu ester) conjugation was per-
formed one more time. After the cleavage of the (NOTA)8-NH2 mixture from resin
in a cocktail of TFA (95%), water (2.5%), and TIPS (2.5%), (NOTA)8-NH2 (n= 2,
13 ± 2 mg, 2.8 μmol) was isolated by HPLC (acetonitrile gradient from 5% to 60%
with 0.1%TFA solution for 30 min, retention time: 15.5 min). The mass of
(NOTA)8-NH2was confirmed by MALDI-TOF ([M+H+], exact mass was cal-
culated at 4627.62 and found at 4627.20 Da) (Supplementary Fig. 2a).
Synthesis of (NOTA)8-transcyclooctene (TCO). To a solution of (NOTA)8-NH2
(1, 3.3 mg, 0.7 μmol) in 1x PBS (1 mL, pH 7.8), transcyclooctene-PEG4-NHS
(TCO-PEG4-NHS, 10 mg, 19 μmol,) dissolved in DMSO (80 μL) was added. pH
was readjusted to 8, and the reaction mixture was stirred in a vortex mixer at
room temperature for 2–3 h. The solution was diluted with double distilled-water
(3–4 mL) and concentrated using a 3 kDa MWCO spin filter unit. Dilution and
concentration steps were repeated. (NOTA)8-TCO (2, 1 mg, 0.4 μmol) was isolated
by HPLC (acetonitrile gradient from 5% to 60% with 0.1%TFA solution for 30 min,
retention time: 24.4 min). Mass of (NOTA)8-TCO was confirmed by MALDI-TOF
(Supplementary Fig. 2a).
Synthesis of (NOTA)8-A555-TCO. (NOTA)8-cys(SH)-NH2 (4) was similarly
synthesized by adding cysteine and a mono-PEG sequence between PEG27 and the
lysine from (NOTA)8-TCO as shown in Supplementary Fig. 2b. After isolation of
the product with HPLC, the MALDI-TOF spectrum confirmed the mass of
(NOTA)8-cys(SH)-NH2. (NOTA)8-cys(SH)-NH2 (2 mg, 0.41 μmol) was reacted
with AF555-maleimide (1 mg, 0.79 μmol, Fluoroprobe, Az) in PBS, then the iso-
lation with 3 kDa MWCO spin filter and HPLC afforded (NOTA)8-A555-NH2 (5,
1 mg, 0.17 μmol). (NOTA)8-A555-NH2 (1 mg, 0.17 μmol) reacted with TCO-PEG4-
NHS (3 mg, 5.8 μmol) in 1xPBS (1 mL, pH 8) gave (NOTA)8-A555-TCO (6, 350
μg, 0.06 μmol) after HPLC purification (Supplementary Fig. 2b). The AF555, the
fluorophore in AF555-MI, is denoted as A555 in the conjugated form.
Synthesis of (NOTA)8-maleimide (MI). To a solution of (NOTA)8-NH2 (1, 2 mg,
0.7 μmol) in 1x PBS (0.5 mL, pH 7.4), 0.1 M EDTA (10 μL) and SM(PEG)2 (NHS-
PEG2-MI, 4 mg, 9.4 μmol) dissolved in DMSO (30 μL) were added. The reaction
mixture was stirred in a vortex mixer at room temperature for 1 h. The solution
was then diluted with 0.05% TFA in water (3–4 mL) and concentrated using a 3
kDa MWCO spin filter unit. Dilution and concentration steps were repeated.
(NOTA)8-MI (3, 1 mg, 0.2 μmol) was isolated by HPLC (acetonitrile gradient from
5% to 60% with 0.1%TFA solution for 30 min, retention time: 16.6 min). Mass of
(NOTA)8-MI) was confirmed by MALDI-TOF ([M+H+], exact mass was cal-
culated at 4937.74 and found at 4937.66) (Supplementary Fig. 2a).
Titration and LC-MS/MS. Detailed methods for the titration of single- and
multichelators with Cu-63/Cu-64 (shown in Supplementary Fig. 3) and for LC-MS/
MS analysis of the Tz-PHP.eB capsid (shown in Supplementary Table 2) are
available in the Supplementary Methods section.
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In vitro evaluation of PHP.eB transduction before and after surface amine
modification with Tz-NHS ester. To PHP.eB:CAG-GFP (6.3 × 1012 vg, 10 pmol)
in 1x PBS (350 μL, pH adjusted to 8 with 0.1 M Na2CO3 solution (pH 9.1)), 5 mM
tetrazine-PEG5-NHS (1 μL, 5 nmol) in anhydrous DMSO was added. After incu-
bation for 1.5 h at room temperature, the reaction mixture was dialyzed in a mini-
dialysis device (20 kDa molecular weight cut-off (MWCO)) in 500 mL 1x PBS
overnight at 4 °C. The transduction of CAG-GPF by Tz-PHP.eB and PHP.eB was
compared in HEK293T cells seeded at a density of 70% in a 24-well plate (3×104
cells/well) with 500 μL of Dulbecco’s Modified Eagle’s medium (DMEM; Invitro-
gen) supplemented with 10% fetal bovine serum (FBS; Invitrogen) and 1%
penicillin–streptomycin (Invitrogen) (DMEMc). After incubation at 37 °C and 5%
CO2 for 24 h, media was aspirated and replaced with fresh DMEMc (250 μL) at 1 ×
106 vg/cell of PHP.eB and Tz-PHP.eB. Cells were then incubated at 37 °C in a 5%
CO2 chamber for 24 h in virus-loaded media, and fluorescent microscopy images
(Fig. 2a) were acquired before aspiration and replacement with 500 μL fresh
DMEMc. Cells were cultured for one additional day prior to collection. Media was
aspirated, and PBS (300 μL) was added. Cells were trypsinized and transferred to
1.5 mL centrifuge tubes. Cells were centrifuged at 1500 rpm for 3 min at room
temperature and then washed with 1x PBS. This cell washing cycle was repeated
two times. In all, 4% paraformaldehyde (PFA) was added, and the pelleted cells
were further kept for 10 min at room temperature to fix the cells. Fixed cells were
centrifuged and PFA solution removed. Cells were washed with 1x PBS (500 μL),
centrifuged, and supernatant removed. This washing cycle was repeated two times.
After cells were resuspended in 1x PBS (500 μL) and transferred to 5 mL flow
cytometer tubes on ice, the frequency of green fluorescent cells was analyzed using
a flow cytometer (BD FACScan with 488 nm excitation laser) and FlowJo
v10.1 software (TreeStar) (Fig. 2b). Methods required for the subsequent evaluation
of (NOTA)8-PHP.eB transduction (Supplementary Fig. 4) are provided in
the Supplementary Methods.
In vitro evaluation of AAV9 transduction before and after surface amine
modification with Tz-NHS ester. AAV9:CAG-mNeonGreen (1 × 1013 vg, 17 pmol)
in 1x PBS (440 μL, pH adjusted to 8 with 0.1 M Na2CO3 solution (pH 9.1)), 10 mM
tetrazine-PEG5-NHS (1 μL, 10 nmol) in anhydrous DMSO was added. After
reaction and dialysis in 1xPBS, transduction of CAG-mNeonGreen by Tz-AAV9
and AAV9 (Fig. 2a, b) was compared in HEK293T cells using the same procedure
as above.
In vitro evaluation of AAV9-TC transduction before and after tetracysteine
modification with TCEP. AAV9-TC:CAG-mNeonGreen samples (5.8 × 1012 vg, 10
pmol) in 1x PBS (100 μL) were incubated for 30 min at room temperature after the
addition of 5 mM TCEP (5 nmol, 1 μL). The reaction mixture was dialyzed in a
mini-dialysis device (20 kDa molecular weight cut-off (MWCO)) in 500 mL 1x PBS
overnight at 4 °C. Transduction of CAG-mNeonGreen by HS-AAV9-TC and
AAV9-TC (Fig. 2a, b) was compared in HEK293T cells using the same procedure
as above. Methods required for the subsequent evaluation of (NOTA)8-AAV9-TC
transduction (Supplementary Fig. 5) are provided in the Supplementary Methods.
Sodium dodecyl sulfate—polyacrylamide gel electrophoresis of AAVs. AAVs
used for in vitro transduction and in vivo PET studies were concentrated to 20 μL
and 150 μL volume, respectively, using a spin filter (MWCO 100k). AAV capsids
(5–10 μL) were denatured in tris-glycine Sodium dodecyl sulfate (SDS) sample
buffer (ThermoFisher Scientific, LC2676) and treated for 2 min at 85 °C. This
solution was loaded into and separated on a 14% tris-glycine mini gel (Thermo-
Fisher Scientific, XP00140BOX) under 225 V for 45 min in an electrophoresis
chamber filled with tris-glycine SDS running buffer (ThermoFisher Scientific,
LC2675). Sharp pre-stained protein standard ladder protein images (ThermoFisher
Scientific, LC5800) were loaded to compare the molecular weight of viral proteins.
The gel was washed with double distilled water, stained with Coomassie staining
solution (ThermoFisher Scientific, LC6060) and imaged using an iPhone 6 cellular
phone camera (Fig. 2e, Supplementary Figs. 4b and 5b). The gels loaded with
radiolabeled AAVs were further exposed on a phosphor screen in a cassette
(Molecular Dynamics, CA) overnight, which was then scanned using the Phos-
phorimager (Amersham Bio-Science, NJ). For polyacrylamide gel electrophoresis
(PAGE) of AAVs in Supplementary Figs. 4b and 5b, the same procedure was
performed without gel autoradiography.
In vivo transduction assay with 63Cu-PHP.eB and PHP.eB. The synthesis of Cu-
PHP.eB was performed by the following procedure. Tetrazine-PEG5-NHS in
anhydrous DMSO (1 μL, 0.5 mM) was added to PHP.eB:CAG-GFP (2.1 × 1012 vg,
3.5 pmol) in 1x PBS (180 μL, pH adjusted to 8 with 0.1 M Na2CO3 solution (pH
9.1)). After incubation for 1 h at room temperature, the reaction mixture was
dialyzed in a mini-dialysis device (20 kDa molecular weight cut-off (MWCO)) at 4
°C overnight. The dialyzed solution was incubated with copper-incorporated
(NOTA)8-TCO (5 μL, 10 μM) for 30 min and then diluted to 15 mL with PBS. The
solution was concentrated using a centrifugal filter unit (MWCO 100k, 3000×g for
10 min). Dilution in 15 mL PBS and concentration was repeated twice. The size of
the isolated 63Cu-PHP.eB and non-labeled PHP.eB was measured using a Zetasizer
(Malvern). After titration of the 63Cu-PHP.eB and the non-labeled PHP.eB
solution, 1.5 × 1010 vg of 63Cu-PHP.eB:CAG-GFP or PHP.eB:CAG-GFP as a control
were injected in C57BL/6 mice (n= 2 per group). After three weeks, mice were
euthanized by Euthosol under deep isoflurane and perfused with DMEM followed
by 4% paraformaldehyde (in PBS). The harvested brains were further fixed in 4%
paraformaldehyde (PFA) in PBS for a day. Fluorescent images of the sliced
brain were aquired and quantified (Fig. 2c, d).
Radiolabeling of AAVs. All radiolabeling experiments were conducted under a
radiation use authorization approved by the University of California, Davis (Davis,
CA) and Stanford University (Palo Alto, CA). Molar activity in Fig. 1 is calculated
from the average molar activity described in the quality control report from the
Washington University, School of Medicine MIR cyclotron facility (the source of
Cu-64 used in this study). For radiolabeling of AAV9 and PHP.eB, pH of AAV9:
CAG-mNeonGreen (1 × 1013 vg, 16 pmol in 0.4 mL PBS) and PHP.eB:CAG-GFP
(4.2 × 1012 vg, 7 pmol in 0.2 mL PBS) was adjusted to 8 with 0.1 M Na2CO3
solution (pH 9.2), and 1 mM tetrazine-PEG5-NHS (1 nmol, 1 μL) in anhydrous
DMSO was added to the AAV solutions. The reaction mixtures were incubated at
4 °C for 2 h, transferred to a mini-dialysis device (20 kDa molecular weight cut-off
(MWCO)), and dialyzed in 1x PBS (0.5 L) overnight. Tetrazine-conjugated AAVs
(Tz-AAVs) were further reacted with 64Cu-chelated (NOTA)8-TCO for 30 min,
freshly prepared from a reaction of 64CuCl2 (37-74 MBq (1–2 mCi), 2–3 μL) and
10 μM (NOTA)8-TCO (20 pmol, 2 μL) in ammonium citrate buffer (10 μL, pH 6.5).
The incorporation of Cu-64 to (NOTA)8-TCO was monitored by instant thin-layer
chromatography and completed in 30 min. Radiolabeled AAVs (64Cu-AAV9 and
-PHP.eB) were purified by size-exclusion chromatography (bed volume: 3 mL) or
centrifugal filter unit (MWCO 100k, 3000 g for 10 min) with three cycles of dilu-
tion with PBS (15 mL) and concentrated in ~200 μL volume. For radiolabeling of
AAV9-TC, AAV9-TC:CAG-mNeonGreen (3 × 1013 vg, 50 pmol, in 0.1 mL PBS)
was treated with 5 mM tris(2-carboxyethyl)phosphine (TCEP) (5 nmol, 1 μL) for
30 min. 64Cu-chelated (NOTA)8-MI, obtained from the incorporation of 64CuCl2
(74 MBq (2 mCi), 2.5 μL) to 10 μM (NOTA)8-MI (35 pmol, 3.5 μL) in ammonium
citrate buffer (10 μL, pH 6.5), was added to disulfide-reduced SH-AAV9-TC and
then the pH adjusted to 7–7.5 with 0.1 M NaOH. After incubation at room tem-
perature for 1 h, 64Cu-AAV9-TC was isolated by size-exclusion chromatography
and concentrated in ~200 μL volume.
PHP.eB and AAV9 labeling with (NOTA)8-A555-TCO for the characterization
of the number of labels per AAV particle. PHP.eB:CAG-mNeonGreen (1.2 ×
1012 vg, 2 pmol) or AA9:CAG-mNeonGreen (2 × 1012 vg, 3.3 pmol) in PBS buffer
(pH 8, 0.1 mL) was reacted with tetrazine-PEG5-NHS (0.4–0.7 and 0.7–1 equiva-
lents, respectively) at room temperature for 30 min. After addition of 0.1 mL PBS,
the reaction mixture was dialyzed (MWCO 20k) in PBS buffer three times (15 mL
each dialysis for 2 h and 50 mL overnight). Dialyzed Tz-PHP.eB or -AAV9 mix-
tures were reacted with (NOTA)8-A555-TCO (20-40 and 30-50 pmol, respectively)
for 30 min at room temperature. Reaction mixture was diluted to 15 mL with PBS
and filtered in a centrifugal filter unit (MWCO 100k, 3000×g for 10 min). To the
concentrated product in PBS (~0.15 mL), PBS (15 mL) was added and centrifuged
(MWCO 100k, 3000×g for 10 min). The concentrated solution (~0.15 mL) was
transferred to a centrifugal tube, and the volume was adjusted to 0.2 mL. The
number of AAVs and labels were then measured (Supplementary Table 3).
AAV9-TC labeling with A555-C2-MI for the characterization of the number of
labels per AAV particle. AAV9-TC:CAG-mNeonGreen (1.7 × 1012 vg, 3 pmol) in
PBS (pH 7, 0.1 mL) was treated with 0.1 mM tris(2-carboxyethyl)phosphine
(TCEP) (0.3 nmol) for 30 min. Alexa555-C2-MI (60 pmol) in dissolved in anhy-
drous DMSO was added to a reduced form of AAV9-TC (SH-AAV9-TC). After
incubation at room temperature for 1 h, the reaction mixture was diluted with 15
mL PBS and filtered in a centrifugal filter unit (MWCO 100k, 3000×g for 10 min).
To a concentrated product in PBS (~0.15 mL), PBS was added again and cen-
trifuged (MWCO 100k, 3000×g for 10 min). Concentrated solution (~0.15 mL) was
transferred to a centrifugal tube, and the volume was adjusted to 0.2 mL. The
number of AAVs and labels were then measured. The resulting optical label is
denoted as A555 at Supplementary Table 3.
PHP.eB and AAV9 labeling with A555 for in vivo optical imaging. PPHP.eB:
CAG-DIO-GFP and AAV9:CAG-mNeonGreen was directly labeled with Axexa555-
NHS ester. In brief, 1 mM Alexa555-NHS (2 μL in DMSO, 2 nmol) was added to
PHP.eB (7 × 1012 vg, 12 pmol) or AA9 (5.2 × 1012 vg, 7 pmol) in PBS buffer (pH 8).
After 1 h, the mixture was transferred to a mini-dialysis device (20 kDa molecular
weight cut-off (MWCO) and dialyzed in 1xPBS (0.5 L) overnight. The dialyzed
solution was diluted with 15 mL of PBS solution and filtered in a centrifugal filter
unit (MWCO 100k, 3000×g for 10 min) with three cycles of dilution with PBS (15
mL). This solution was reformulated with 1x PBS before the in vivo
study shown in Supplementary Fig. 9. The resulting label is denoted as A555 in
Supplementary Figs. 7a and 9.
PHP.eB and AAV9 labeling with (NOTA)8-A555-TCO for in vivo optical
imaging. PHP.eB:CAG-DIO-GFP and AAV9:CAG-mNeonGreen was labeled with
tetrazine-PEG5-NHS using the same procedure as above. In brief, 1 mM tetrazine-
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PEG5-NHS (2 μL in DMSO, 2 nmol) was added to PHP.eB (1.4 × 1013 vg, 23 pmol)
in PBS buffer (pH 8). After 1 h, the mixture was transferred to a mini-dialysis
device (20 kDa molecular weight cut-off (MWCO)) and dialyzed in 1x PBS (0.5 L)
overnight. Tz-PHP.eB solution was reacted with 0.1 mM (NOTA)8-A555-TCO (1
μL, 0.1 nmol) for 30 min at room temperature. The reaction mixture was diluted to
15 mL PBS solution and filtered in a centrifugal filter unit (MWCO 100k, 3000 g for
10 min) with three cycles of dilution with PBS (15 mL). Concentrated (NOTA)8-
A555-PHP.eB was formulated with 1x PBS for the in vivo study shown in Fig. 3i
and Supplementary Fig. 10.
Animal models. All animal experiments were conducted under an animal use
protocol approved by the University of California, Davis, Institutional Animal Care
and Use Committee (IACUC) or Stanford University, Administrative Panel on
Laboratory Animal Care (APLAC). For PET studies and biodistribution, 64Cu-
labeled AAVs were evaluated in wild-type 7–9-week-old female C57BL/6 and
9 week-old-female BALB/c mice (The Jackson laboratory, Bar Harbor, ME). For
neuraminidase-treated BALB/c mice, neuraminidase (0.12 units/20 μL, Sigma-
Aldrich, #N7885) was intranasally administered 3 h before the injection of 64Cu-
AAVs. The classical pharmacokinetics and biodistribution studies with qPCR were
conducted with wild-type 5–6 week-old female C57BL/6 mice (Charles River).
PET/CT scans and biodistribution. Mice were anesthetized with 3.0% isoflurane
in oxygen and maintained under 1.5–2.0% isoflurane. 64Cu-AAV9 injections in
C57BL/6 mice (n= 3, 421 ± 25 KBq), 64Cu-AAV9-TCO injections in C57BL/6
mice (n= 3, 760 ± 156 KBq), 64Cu-PHP.eB injections in C57BL/6 mice (n= 3, 628
± 581 KBq), BALB/c mice (n= 3, 477 ± 19 KBq), or BALB/c mice treated with
neuraminidase (n= 3, 718 ± 30. KBq) were administered via the tail vein on an
Inveon DPET small animal PET scanner (Siemens Medical Solutions USA,
Knoxville, TN). Animals were scanned for 30 min at 0, 4, and 21 h post injection.
After each PET scan, the animals were moved to a small animal Inveon MM CT
system (Siemens Medical Solutions USA, Knoxville, TN) and a CT scan was
conducted to obtain anatomical information for co-registration of PET/CT images.
After the final imaging time point, mice were euthanized by Euthosol under deep
isoflurane. Animals were then perfused with DMEM solution. Blood, heart, lungs,
liver, spleen, kidneys, stomach, intestine, muscle, bone, and brain were harvested
for biodistribution analysis. Radioactivity in each organ was measured with a 1470
automatic gamma counter (PerkinElmer, CT) after which organ weights were taken
on a balance. Biodistribution of AAVs was presented as percent injected dose per
gram (% ID/g). In some cases, brains were sectioned at 2 mm thickness to obtain
ex vivo autoradiography.
ROI analysis and time–activity curves. All PET images were reconstructed with
the maximum a posteriori (MAP) reconstruction algorithm in Inveon Acquisition
Workspace (Siemens Medical Solutions Inc., USA) and analyzed with Inveon
Research Workspace 4.2 (Siemens Medical Solutions Inc., USA) after the co-
registration of PET/CT images. Regions of interest (ROIs) were drawn in the heart
chamber for blood, whole brain, and liver. The time-activity curves (TAC) of blood,
brain, and liver radioactivities at 0, 4, and 21 h were analyzed with Prism 8
(Graphpad). Blood TACs were fitted with one phase decay. Radioactivity density
from image analysis is presented as percent injected dose per cubic centimeter (%
ID/cc).
Early brain accumulation and Logan analysis of 64Cu-AAVs. Initial PET data
from the 30 min scan was segmented into six frames (5 min/frame). Blood radio-
activity in the brain (% ID/cc) over time was calculated by multiplying the brain
radioactivity by the brain vascular volume (8%) (estimated by the ratio of brain and
blood radioactivity of AAV9 and AAV9-TC in C57BL/6 and PHP.eB in BALB/c at
5 min after injection). The blood radioactivity over time was then subtracted from
total brain activity (% ID/cc) to estimate the brain accumulation. A Logan plot
(Fig. 3h) was then applied for the calculation of the uptake rate of each AAV in the
brain at a given time after the administration of AAVs17. CB(t) and CT(t) are the
radioactivity concentration in the blood and target at a given time, and IntCB(t)
and IntCT(t) are the accumulated radioactivity in the blood and target, respectively,
from the time of injection to time (t). IntCT(t)/CT(t) vs IntCB(t)/CT(t) was then
plotted.
Confocal microscopy. For imaging of fluorescent AAVs (Fig. 3i and Supple-
mentary Fig. 9), mice were anesthetized with 3.0% isoflurane in oxygen and
maintained under 1.5–2.0% isoflurane. A555-PHP.eB (0.1 mL, 1 × 1011 vg) or
(NOTA)8-A555-PHP.eB (0.1 mL, 2 × 1010 vg) or was administered to C57BL/6
mice (n= 14 total) through tail vein injection. Mice were euthanized at 4, 24 and
48 h by Euthosol under deep isoflurane, and perfused with DMEM solution fol-
lowed by 4% PFA in PBS at pH 7. To stain the brain endothelium, FITC-lectin (25
μL, 50 μg) was injected via the tail-vein 15 min before euthanization. Brains were
collected and kept in 4% PFA overnight. Brain tissue was then sliced to 100 μm
thick sections on a vibratome (Leica VT-1000S) in PBS and mounted onto
microscope slides. Fluorescence images of AAV distribution on the endothelium
were acquired with a confocal microscope (Zeiss AxioObserver), a ×40 objective,
488 and 561 nm lasers, and HQ camera. The microscope was controlled by Sli-
debook software (Intelligent Imaging Innovations).
Brain slices for in vivo transduction (Figs. 2c and 3g) were mounted on
microscope slides and imaged using a confocal microscope (Leica DMi8) controlled
with LAS X software. All images were recorded at the same laser power and gain
control. Images were acquired with a 10x lens and fluorescence images were
analyzed using ImageJ.
Synthesis of PEG(40 kDa)-AAV9 for cryo-electron microscopy. To a solution
(0.4 mL, PBS) of PEG(40 kDa)-NH2 (2.5 mg, 62 nmol) was added TCO-PEG4-NHS
ester (0.5 mg, 0.86 μmol). The pH was adjusted to 8.6 with 0.1 M sodium carbonate
(pH 9.2). After a 2 h reaction at room temperature, the reaction mixture was
diluted with 1 mL deionized water then dialyzed overnight with 10k MWCO and
the purified solution was transferred to a cryotube and freeze-dried (Supplemen-
tary Fig. 7b). PEG(40 kDa)-AAV9 was obtained as illustrated in Supplementary
Fig. 7a. Tz-AAV9 was obtained from a reaction with AA9:CAG-mNeonGreen
(5.9 × 1012 vg, 9.8 pmol) and tetrazine-PEG5-NHS (2 μL in DMSO, 2 nmol) under
the same procedure as in Optical labeling of AAVs and was reacted with 10 μM
PEG (40 kDa)-TCO (4 μL, 40 pmol) for 30 min at room temperature. The reaction
mixture was diluted to 15 mL PBS solution and filtered in a centrifugal filter unit
(MWCO 100k, 3000 g for 10 min) with two cycles of dilution with PBS (15 mL).
PEG (40 kDa)-AAV9 was further concentrated to 40 μL volume for cryo-EM.
Cryo-electron microscopy of PEG(40 kDa)-AAV9. Cryo-Electron microscopy
collection was performed on a Glacios™ Cryo-TEM operating with a field-emission
gun at 200 kV. Cryo-EM grid was prepared with a 30 μL solution containing PEG
(40 kDa)-AAV9, which was placed on Quantifoil R1/2 Cu 300 mesh grids. The
grids were pretreated with 10 mAmp of glow discharge for 40 seconds. After 1 min
of on-grid incubation the excess solution was removed and quickly plunged into
liquid ethane using an FEI Vitrobot Mark III semi-automated cryo-plunger. The
PEG(40 kDa)-AAV9 particles were embedded into a thin layer of vitrified ice and
transferred into the imaging chamber using a Gatan 626 cryo-transferring system.
The grids were examined at ×50,000 magnification and images were captured using
a Gatan K3. The cryoEM images were inverted in contrast to illustrate the positive
density of the molecular mass against the dark ice background. The digital images
were recorded with a pixel size of 0.85 Å using autofocusing scripts in the Serial-
EM package set to a defocus range of 0.5–2.0 micron. The digital images with
minimum stigmatism or drift were selected for further statistical analysis and figure
preparation. Corresponding EM images are shown in Fig. 2g.
Biodistribution and pharmacokinetics of AAVs with qPCR. For the biodis-
tribution study in Fig. 3f, g, PHP.eB (7.4 × 1010 vg, n= 4) and (NOTA)8-A555-
PHP.eB (1.4 × 1011 vg, n= 4) in PBS (0.1 mL) were injected through the mouse
(C57BL/6) tail vein. At 21 h after injection, mice were euthanized by Euthosol
under deep isoflurane, and then perfused with DMEM. Heart, lungs, liver, spleen,
kidneys, brain, and blood were harvested as 3–4 fractions per tissue and 100–200
μL blood per mouse. Collected tissues were immediately frozen in 2 mL cryotubes
under liquid nitrogen and stored at −80 °C. Viral vector and mouse genomic
DNAs were extracted from tissues by a DNeasy Blood and Tissue Kit (Qiagen)
according to the kit protocol and quantified by quantitative polymerase chain
reaction (qPCR) with a TaqMan assay. The primers and TaqMan probe used for
the WPRE sequence were 5′-GCATTGCCACCACCTGTCA (forward) and 5′-
TCCGCCGTGGCAATAGG (reverse), and 5′-CTTTCCGGGACTTTCG (FAM).
The primers and TaqMan probe targeting the mouse glucagon gene as a house-
keeping gene were 5′-GTTCTCTCTGTATTGTCCTTTCAAAGTCT (forward)
and 5′-CAAAGTCCCTGAAGGTTCTGAGATG (reverse), and 5′-CCCTGGTC
ATGTTTTTAA (FAM). Quantification was performed by a standard curve from a
serial dilution of known standard plasmid concentration. For the classical PK study
of blood clearance, PHP.eB (1.35 × 1011 vg, n= 4) and (NOTA)8-A555-PHP.eB
(1.17 × 1011 vg, n= 4) in PBS (0.1 mL) were injected through the mouse (C57BL/6)
tail vein. Blood (~100–200 μL) was collected from the mouse orbital sinus at 0.5, 4,
and 21 h after administration to a Microtrainer containing EDTA (BD science, NJ).
Collected blood was immediately transferred to 2 mL cryotubes (Sarstedt, Ger-
many) and further frozen in liquid nitrogen. The viral vectors from 100 μL of blood
were extracted by DNeasy Blood and Tissue Kit (Qiagen) according to the kit
protocol and quantified by the TaqMan assay targeting the WPRE sequence. qPCR
was performed with QuantStudio6 Flex (Applied Biosystems) and CFX96 Touch
real-time PCR detection system (Bio-Rad).
Image processing and data analysis. Microscopic image process and ROI ana-
lyses were performed using ImageJ, LAS X (Leica) and SlidBook6 (3i). For PET/CT
data and image processing, Inveon Acquisition Workspace (Siemens) and Inveon
Research Workspace 4.2 (Siemens) was used, respectively. Microsoft Excel (ver.
16.35), and GraphPad Prism 8 for macOS were used for general data and statistical
analysis. PyMOL 2.0 (Molecular Graphics System) was used to process the struc-
ture of capsid. FlowJo v10.1 (Treestar) was used for data analyses of results from
flow cytometry. Gating/sorting strategy is presented at Supplementary Fig. 11 and
reporting summary.
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Statistics and reproducibility
All statistical analyses were performed in GraphPad Prism soft-
ware (Prism 8.0). The statistical tests with confidence intervals,
effect sizes, degree of freedom and P values can be found in the
source data. Sample size for each experiment is shown in the
appropriate caption and the biological replicates across experi-
ments are summarized below. Cell experiments in Fig. 2a, b were
repeated 4, 3, and 1 times for PHP.eB, AAV9 and AAV9-TC. For
Fig. 2c, fluorescent images were selected from multiple mouse
brain slices obtained in 2 experiments. For Fig. 2g, the cryoEM
images result from a single experiment. For Fig. 3a–e and G-H,
PET/CT and autoradiography result from two experiments. For
Fig. 3f, qPCR results were obtained from one set of experiments.
For Fig. 3i, representative fluorescence images with the multi-
chelator AAV were chosen from mice euthanized at 4 (two
experiments), 24 (one experiment) and 48 h (one experiment).
For Fig. 4, the data result from one series of experiments.
Reporting summary. Further information on research design is
available in the Nature Research Reporting Summary linked to
this article.
Data availability
The raw data files from mass spectrometer were processed using Byonic v 2.14.27
(Protein Metrics, San Carlos, CA) to identify peptides and subsequently infer proteins
using the Mus musculus database from the Universal Protein Resource (UniProt, http://
www.uniprot.org) along with the sequences of capsid proteins. Protein Data Bank (PDB
ID:3Ux1) was used to display capsid structure. Analyzed viral protein sequence data are
available in the source data. The authors declare that image and quantitative data
supporting the findings of this study are available within the paper and the source data
and supplementary files. The raw PET images and associated data that support the
findings of this study are available from the corresponding author upon reasonable
request.
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